Vivo Capital LLC Invests $6.38 Million in ALX Oncology Holdings Inc. $ALXO

Vivo Capital LLC acquired a new position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 3,184,713 shares of the company’s stock, valued at approximately $6,385,000.

Several other institutional investors also recently modified their holdings of the business. Bank of America Corp DE boosted its stake in ALX Oncology by 8.6% in the first quarter. Bank of America Corp DE now owns 577,783 shares of the company’s stock valued at $1,158,000 after acquiring an additional 45,938 shares during the last quarter. Redmile Group LLC boosted its holdings in ALX Oncology by 143.9% during the first quarter. Redmile Group LLC now owns 7,964,188 shares of the company’s stock worth $15,968,000 after buying an additional 4,699,470 shares during the last quarter. venBio Partners LLC grew its position in shares of ALX Oncology by 32.8% during the 1st quarter. venBio Partners LLC now owns 12,884,638 shares of the company’s stock worth $25,834,000 after buying an additional 3,184,713 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of ALX Oncology in the 1st quarter valued at approximately $5,747,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in ALX Oncology during the first quarter valued at approximately $150,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

ALX Oncology Trading Up 0.3%

NASDAQ ALXO opened at $1.95 on Friday. ALX Oncology Holdings Inc. has a 12 month low of $0.51 and a 12 month high of $2.66. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average of $1.88 and a 200-day moving average of $1.91. The company has a market cap of $262.40 million, a PE ratio of -1.31 and a beta of 0.42.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). On average, equities research analysts anticipate that ALX Oncology Holdings Inc. will post -0.66 EPS for the current fiscal year.

Analyst Ratings Changes

ALXO has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of ALX Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of ALX Oncology in a report on Friday, June 26th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $4.60.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.